These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 31418764)

  • 1. Advances in targeted alpha therapy for prostate cancer.
    De Vincentis G; Gerritsen W; Gschwend JE; Hacker M; Lewington V; O'Sullivan JM; Oya M; Pacilio M; Parker C; Shore N; Sartor O;
    Ann Oncol; 2019 Nov; 30(11):1728-1739. PubMed ID: 31418764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study.
    Stuparu AD; Meyer CAL; Evans-Axelsson SL; Lückerath K; Wei LH; Kim W; Poddar S; Mona CE; Dahlbom M; Girgis MD; Radu CG; Czernin J; Slavik R
    Theranostics; 2020; 10(6):2612-2620. PubMed ID: 32194823
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with
    Kratochwil C; Bruchertseifer F; Rathke H; Bronzel M; Apostolidis C; Weichert W; Haberkorn U; Giesel FL; Morgenstern A
    J Nucl Med; 2017 Oct; 58(10):1624-1631. PubMed ID: 28408529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.
    Kratochwil C; Bruchertseifer F; Giesel FL; Weis M; Verburg FA; Mottaghy F; Kopka K; Apostolidis C; Haberkorn U; Morgenstern A
    J Nucl Med; 2016 Dec; 57(12):1941-1944. PubMed ID: 27390158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    Sartor O; de Bono J; Chi KN; Fizazi K; Herrmann K; Rahbar K; Tagawa ST; Nordquist LT; Vaishampayan N; El-Haddad G; Park CH; Beer TM; Armour A; Pérez-Contreras WJ; DeSilvio M; Kpamegan E; Gericke G; Messmann RA; Morris MJ; Krause BJ;
    N Engl J Med; 2021 Sep; 385(12):1091-1103. PubMed ID: 34161051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
    Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
    J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of
    Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
    Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of
    Violet J; Sandhu S; Iravani A; Ferdinandus J; Thang SP; Kong G; Kumar AR; Akhurst T; Pattison DA; Beaulieu A; Mooi J; Tran B; Guo C; Kalff V; Murphy DG; Jackson P; Eu P; Scalzo M; Williams S; Hicks RJ; Hofman MS
    J Nucl Med; 2020 Jun; 61(6):857-865. PubMed ID: 31732676
    [No Abstract]   [Full Text] [Related]  

  • 9. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study.
    Sathekge MM; Lawal IO; Bal C; Bruchertseifer F; Ballal S; Cardaci G; Davis C; Eiber M; Hekimsoy T; Knoesen O; Kratochwil C; Lenzo NP; Mahapane J; Maserumule LC; Mdlophane AH; Mokoala KMG; Ndlovu H; Pant V; Rathke H; Reed J; Sen IB; Singh A; Sood A; Tauber R; Thakral P; Yadav MP; Morgenstern A
    Lancet Oncol; 2024 Feb; 25(2):175-183. PubMed ID: 38218192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Experience with [
    Alan-Selcuk N; Beydagi G; Demirci E; Ocak M; Celik S; Oven BB; Toklu T; Karaaslan I; Akcay K; Sonmez O; Kabasakal L
    J Nucl Med; 2023 Oct; 64(10):1574-1580. PubMed ID: 37620050
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Sathekge M; Bruchertseifer F; Knoesen O; Reyneke F; Lawal I; Lengana T; Davis C; Mahapane J; Corbett C; Vorster M; Morgenstern A
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):129-138. PubMed ID: 30232539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Theranostics in Prostate Cancer.
    O'Dwyer E; Bodei L; Morris MJ
    Semin Radiat Oncol; 2021 Jan; 31(1):71-82. PubMed ID: 33246638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer.
    Alati S; Singh R; Pomper MG; Rowe SP; Banerjee SR
    Semin Nucl Med; 2023 Sep; 53(5):663-686. PubMed ID: 37468417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with
    Kratochwil C; Bruchertseifer F; Rathke H; Hohenfellner M; Giesel FL; Haberkorn U; Morgenstern A
    J Nucl Med; 2018 May; 59(5):795-802. PubMed ID: 29326358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TheraP: a randomized phase 2 trial of
    Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
    BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Status of Prostate-specific Membrane Antigen-targeted Alpha Radioligand Therapy in Prostate Cancer.
    Yamamichi G; Kato T; Watabe T; Hatano K; Uemura M; Nonomura N
    Anticancer Res; 2024 Mar; 44(3):879-888. PubMed ID: 38423627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Overview of Targeted Alpha Therapy with
    Morgenstern A; Apostolidis C; Kratochwil C; Sathekge M; Krolicki L; Bruchertseifer F
    Curr Radiopharm; 2018; 11(3):200-208. PubMed ID: 29732998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Alpha Therapy with Thorium-227.
    Frantellizzi V; Cosma L; Brunotti G; Pani A; Spanu A; Nuvoli S; De Cristofaro F; Civitelli L; De Vincentis G
    Cancer Biother Radiopharm; 2020 Aug; 35(6):437-445. PubMed ID: 31967907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials.
    Ramnaraign B; Sartor O
    Oncologist; 2023 May; 28(5):392-401. PubMed ID: 36806966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
    Hagemann UB; Wickstroem K; Hammer S; Bjerke RM; Zitzmann-Kolbe S; Ryan OB; Karlsson J; Scholz A; Hennekes H; Mumberg D; Cuthbertson AS
    Cancer Biother Radiopharm; 2020 Sep; 35(7):497-510. PubMed ID: 32255671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.